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One explanation for the increased incidence of allergies, asthma, and even some autoimmune diseases has
been the hygiene hypothesis. However, recent studies also highlight an important role for diet and bacterial
metabolites in controlling various immune pathways, including gut and immune homeostasis, regulatory
T cell biology, and inflammation. Dietary-related metabolites engage ‘‘metabolite-sensing’’ G-protein-
coupled receptors, such as GPR43, GPR41, GPR109A, GPR120, and GPR35. These receptors are expressed
on immune cells and some gut epithelial cells and generally mediate a direct anti-inflammatory effect. Insuf-
ficient intake of ‘‘healthy foodstuffs’’ adversely affects the production of bacterial metabolites. These metab-
olites and those derived directly from food drive beneficial downstream effects on immune pathways. We
propose that insufficient exposure to dietary and bacterial metabolites might underlie the development of
inflammatory disorders in Western countries. This review highlights what is currently known about diet,
metabolites, and their associated immune pathways in relation to the development of inflammatory disease.Introduction
The incidence of many inflammatory conditions, such as asthma
and allergies, has increased dramatically in Western countries
over the past few decades. Although less dramatic, the inci-
dence of some autoimmune diseases, particularly type 1
diabetes, has also increased. The prevailing hypothesis for
the increased incidence of asthma and allergies has been the
hygiene hypothesis (Strachan, 1989; Strachan, 2000), which
initially proposed that declining family size and improvements
in personal hygiene reduce opportunities for cross-infections
in families and that this leads to dysregulation in the immune
system. As this hypothesis has evolved, it has incorporated the
disruption of the beneficial gut commensal flora, which might
be the real driver of inflammatory disease incidence in the West-
ern world (Noverr andHuffnagle, 2004; Rook et al., 2003). A num-
ber of recent studies highlight the profound effect of diet on gut
microbiota composition and the connection to immunological
pathways (see also reviews by Ahern et al., 2014; Dorrestein
et al., 2014; and Huttenhower et al., 2014, in this issue of
Immunity). Mechanisms by which dietary, bacterial, and primary
metabolites interact with the immune system have been identi-
fied and are outlined in this review. Many of the foodstuffs that
have traditionally been considered healthy, such as dietary fiber,
fish, and elements of the Mediterranean diet, can now be con-
nected to molecular pathways that promote gut health and
immune tolerance. We will provide a brief outline of the epidemi-
ological evidence that supports a dietary basis for the emer-
gence of inflammatory diseases, outline the connection to the
gut microbiota, and then explain mechanisms by which metabo-
lites intersect with the immune system.
Epidemiological Evidence that Supports a Dietary Basis
for Inflammatory Diseases
In addition to improved hygiene, the nutritional change that has
occurred in the Western world over the past few decades andthe more recent ‘‘Westernization’’ of many countries coincide
with the rise in the prevalence of asthma, allergy (Eder et al.,
2006), and certain autoimmune diseases. Indeed, the change
in dietary foodstuffs and the correlation with disease are partic-
ularly evident in epidemiological studies correlating fiber and fat
intake. The average American consumes 16 g of fiber per day,
which is well below the recommended 25–38 g per day, and
individuals in lower socioeconomic groups consume even less
fiber (King et al., 2012). Notably, rural Africans consume substan-
tially more fiber than Western individuals and rarely suffer from
allergies, asthma, or colon cancer. Indeed, high intake of dietary
fiber correlates with a lower risk of death from a range of condi-
tions (Park et al., 2011), including cardiovascular disease and
cancers but also infectious and respiratory diseases.Western in-
dividuals are more likely to eat an ‘‘obesogenic’’ diet, character-
ized by increased consumption of energy-dense, processed
foods and reduced consumption of nutrient-rich foods, such
as fruits and vegetables. A number of studies have discerned
a correlation between asthma incidence and obesity (Boulet,
2013; Dixon et al., 2010; Jensen et al., 2012; Sin and Sutherland,
2008). Furthermore, interventional studies have shown that high
fat (Wood et al., 2011) and low fruit and vegetable (Wood et al.,
2012) consumption is linked to worse asthma outcomes.
Conversely, the Mediterranean diet, which is based on high con-
sumption of vegetables, fruits, olive oil, and fish, has now gained
scientific credibility, at least in the prevention of cardiovascular
diseases and asthma (Berthon et al., 2013; Castro-Rodriguez
et al., 2008; Estruch et al., 2013; Nagel et al., 2010). Others
have also proposed a dietary basis for asthma and allergies on
the basis of convincing epidemiological studies (Devereux,
2006; Eder et al., 2006). A dietary basis for inflammatory dis-
eases is most likely explained by interactions between dietary
or bacterial metabolites and immune cells, or pathways for gut
homeostasis. The current leading metabolites that play protec-
tive roles are short-chain fatty acids (SCFAs), u-3 fatty acids,Immunity 40, June 19, 2014 ª2014 Elsevier Inc. 833
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an emerging field, and there might be many more. Regardless,
there is clear epidemiological evidence supporting a dietary ba-
sis for inflammatory disease. The molecular mechanisms that
link diet, the gut microbiota, metabolites, immune responses,
and inflammatory diseases will be discussed.
Dietary Influences on Gut Microbiota Composition and
Metabolite Production
Humans and other vertebrates have coevolved over millennia
with gut bacteria to the point of reliance on ‘‘commensal’’ bacte-
ria, which might include symbiotic bacteria, for fiber digestion
and the production of metabolites and certain vitamins. Indeed,
diet shapes gut bacterial ecology and diversity (De Filippo et al.,
2010; Le Chatelier et al., 2013; Ou et al., 2013; Turnbaugh et al.,
2008). Furthermore, the composition of the gut microbiota re-
lates to human disease (Clemente et al., 2012; Kau et al., 2011;
Round and Mazmanian, 2009); however, the exact features of
a healthy microbiota have not been fully elucidated. The diversity
of the microbiota can be considered in terms of both richness
(the number of species per sample) and evenness (the relative
abundance of species). In one recent study, individuals with
low bacterial richness (23% of the Danish population) tended
toward adiposity, insulin resistance, and dyslipidemia and a
more pronounced inflammatory phenotype in comparison to in-
dividuals with high bacterial richness (Le Chatelier et al., 2013).
Low bacterial diversity has also been associated with inflamma-
tory bowel disease (IBD) (Lepage et al., 2011; Manichanh et al.,
2006); however, it is unknownwhether this is a cause or a conse-
quence of the disease. Interestingly, in some studies, only a few
bacterial species are necessary for distinguishing between indi-
viduals with high and low bacterial richness (Le Chatelier et al.,
2013). One such species associated with bacterial richness is
Faecalibacterium prausnitzii, which is well characterized for its
anti-inflammatory effects (Sokol et al., 2008), including the ability
of its metabolite(s) (e.g., butyrate) to inhibit NF-kB.
The major metabolites produced by bacteria in the gut are
SCFAs. As more dietary fiber is ingested, SCFA production in-
creases. In one often-quoted study (De Filippo et al., 2010), the
fecal microbiota of European children and rural African children
(from Burkina Faso) were compared. African children showed
higher bacterial richness and a significant enrichment of bacteria
from the generaPrevotella andXylanibacter (efficient at digesting
fiber and producing SCFAs), whereas these bacteria were
completely absent from the microbiota of the European children.
This correlation extended to significantly more SCFAs in the
feces of African children than in the feces of European children
because of their higher consumption of fiber. Notably, themicro-
biota composition of rural Africans is also different from that of
African Americans in that it has a higher proportion of Prevotella
and a lower proportion of Bacteroides, associated with a higher
production of SCFAs, such as butyrate (Ou et al., 2013). In addi-
tion, other important metabolites, such as those related to
tryptophan catabolism (see below), profoundly affect gut ho-
meostasis. To date, there is little information on the relative ability
of different bacterial species to produce various metabolites.
Despite the intense interest in the topic of which features of
commensal bacteria promote gut or immune health, this field is
in its infancy. However, as we assert throughout this article, me-834 Immunity 40, June 19, 2014 ª2014 Elsevier Inc.tabolites such as SCFAs, long-chain fatty acids, and tryptophan
metabolites play a major role in the prevention of inflammatory
disease and are highlighted for their interaction with the immune
system, which might explain at least some of the dietary and
microbiota-related associations with human disease. The next
phase of research will involve the identification of specific blood
and/or fecal metabolites that associate with or protect against
human disease. The coming years should see vastly improved
bioinformatics tools that equate the presence of different bacte-
rial species with enzymaticmachinery and the actual capacity for
the production of various metabolites.
Major Points where Dietary or Bacterial Metabolites
Intersect with the Immune System
It is important to consider where and when dietary metabolites
influence the immune response. Figure 1 illustrates some of
the major points where dietary metabolites intersect with the im-
mune system, i.e., the gastrointestinal (GI) tract, blood, and fetal
environment. Originally, the gut was considered the primary site
where dietary metabolites mediated their effects, through either
gut epithelial integrity or mucosal immunity. Indeed, the distal
colon is where fiber is fermented by commensal bacteria to
produce large quantities of acetate, propionate, and butyrate
(40, 20, and 20 mM, respectively) (Tan et al., 2014). However,
several papers have shown that metabolites (particularly ace-
tate) distribute systemically. Indeed, the exacerbated inflamma-
tory reactions observed in germ-free mouse models of disease
(Herbst et al., 2011; Maslowski et al., 2009) are likely to relate
in part to the absence of SCFAs in the gut, blood, or tissues. In
one recent study, the SCFA propionate was shown to affect den-
dritic cell (DC) and macrophage biology in the bone marrow and
affect T helper 2 (Th2) cell responses in the airways (Trompette
et al., 2014). That circulating SCFAs can have such a profound
effect on systemic macrophage and DC biology illustrates the
strong connection between dietary fiber intake and many types
of immune responses under the control of DCs or macrophages.
Another major point at which metabolites can intersect the im-
mune system is through their transport across the placenta to
the developing fetus, although the full effects of this process
have yet to be determined. Interestingly, the placenta has
recently been shown to contain commensal microbes (Aagaard
et al., 2014). This implicates a potential role for maternal diet
and the commensal microbes in directing immune pathways
during fetal development. Similarly, metabolites such as SCFAs
are present in breast milk, and thismight be an important point of
interaction between metabolites and the immune system. To
date, the role of breast milk in protecting (or promoting) allergies
and asthma is inconclusive. However, high-fat feeding of mice
during lactation predisposes adult offspring to obesity andmeta-
bolic syndrome diseases (Vogt et al., 2014). Further research is
required for determining the relative contribution to the develop-
ment of inflammatory disease at the points where dietary and
bacterial metabolites intersect the immune system.
SCFAs, Major Mediators of Gut Homeostasis
There is amajor role for SCFAs in promoting gut homeostasis. As
we proposed previously, deficiency of dietary fiber might under-
lie poor gut homeostasis, and this somehow contributes to
the development of asthma, allergies, and certain autoimmune
Figure 1. Major Points where Dietary or
Bacterial Metabolites Intersect with the
Immune System
In the GI tract, dietary fiber is primarily digested by
commensal bacteria in the colon, which produces
high concentrations of SCFAs, such as acetate,
propionate, and butyrate. Other metabolites, such
as u-3 fatty acids, succinate, or kynurenic acid,
are directly consumed and absorbed throughout
the GI tract. In addition, metabolites can be
directly absorbed in the small intestine. SCFAs
(mainly acetate) are transported from the gut to the
blood, where they can influence bone marrow and
many cell types throughout the body. Another
major point of intersection is the transfer of me-
tabolites to the developing fetus. SCFAs are able
to cross the placenta or be delivered via breast
milk, where they can influence gene expression
and the development of the immune system.
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years, support for this concept has grown, and newmechanisms
have come to light. Compromised epithelial integrity allows
translocation of bacteria and/or dissemination of their products,
such as food antigens and lipopolysaccharides, from the gut
lumen to tissues, which might potentiate immune cell stimula-
tion. There is considerable evidence that poor GI tract integrity
plays a role in promoting the pathogenesis of autoimmune type
1 diabetes (Vaarala et al., 2008). Moreover, obese mice display
increased intestinal permeability and endotoxemia (Cani et al.,
2009). The aforementioned obesogenic diet disrupts gut flora
ecology and is likely to result in lower production of metabolites
such as SCFAs, which maintain epithelial integrity. Certain
commensal bacteria, such as the acetate-producing Bifidobac-
terium species, have been shown to promote gut epithelial integ-
rity (Fukuda et al., 2011). It is therefore likely that disrupted gut
homeostasis and disrupted immunological tolerance are a cen-
tral mechanism that precedes the development of numerous in-
flammatory diseases.
Some of the major mechanisms whereby commensal bacteria
and SCFAs facilitate gut homeostasis are illustrated in Figure 2.
The first relevant mechanism is ‘‘competitive exclusion,’’
whereby high-fiber diets expand commensal bacteria and thus
limit access of pathogenic bacteria to the gut epithelium. In addi-
tion to the commensals, the mucus barrier is an important
element for physical separation of bacteria from the epithelial
surface and is a critical contributor to both gut homeostasisImmunityand immune tolerance (Shan et al.,
2013). One of the known effects of SCFAs
is promoting the secretion of mucus by
gut epithelial cells (Willemsen et al.,
2003). More specifically, the high-ace-
tate-producing species Bacteroides
thetaiotaomicron has been shown to
promote goblet cell differentiation and
expression of genes for mucus produc-
tion (Wrzosek et al., 2013). Interestingly,
NALP6 is necessary for proper mucus
secretion in the gut (Wlodarska et al.,
2014), and we suspect that SCFA
signaling through metabolite-sensingG-protein-coupled receptors (GPCRs) activates NALP6 (data
not shown). Furthermore, immunoglobulin A (IgA) plays a key
role in maintaining a noninflammatory relationship between the
host and the gut microbiota (Peterson et al., 2007), as well as mi-
crobiota composition (Round and Mazmanian, 2009). Indirect
evidence suggests that SCFAs might also promote the secretion
of IgA by B cells (Ishikawa and Nanjo, 2009). Another point at
which SCFAs operate in the gut is in tissue repair. The gut mu-
cosa is prone to ulceration, and like any other tissue, relies on tis-
sue repair processes. This might be of particular importance in
the GI tract given that ulcers, physical damage, or actions of par-
asites rely on the capacity and efficiency of the repair process.
Point 5 of Figure 2 highlights the role of SCFAs in promoting
regulatory T (Treg) cell responses in the gut (Atarashi et al.,
2011; Atarashi et al., 2013; Geuking et al., 2011; Geuking et al.,
2013). This presumably facilitates immunological tolerance to
food antigens. In one of the first studies to investigate the role
of the gut microbiota in initiating a Treg cell response, Atarashi
et al. colonized germ-free mice with human fecal samples and
then applied a sequential methodology to identify bacterial spe-
cies capable of inducing Treg cells (Atarashi et al., 2013). The
most potent inducers of Treg cells fell within clusters IV, XIVa,
and XVIII of Clostridia. Another study showed that oral inocula-
tion of Clostridia to mice during early life resulted in resistance
to colitis and a reduction in IgE responses (Atarashi et al.,
2011). Although Clostridia species are one of the highest pro-
ducers of the SCFA butyrate, which could explain the ability of40, June 19, 2014 ª2014 Elsevier Inc. 835
Figure 2. Dietary Fiber, SCFAs, and
Mechanisms of Gut Homeostasis
There is now overwhelming evidence of the posi-
tive health benefits of high consumption of dietary
fiber and the associated high concentrations of
SCFAs in the gut (acetate, 40 mM; propionate,
20mM; and butyrate,20mM). The sevenmajor
actions for fiber and SCFAs can be summarized
as follows: (1) ‘‘competitive exclusion,’’ whereby
a high-fiber diet expands commensal bacteria
and limits pathogenic bacteria access to the gut
epithelium; (2) SCFA-induced promotion of mucus
by gut epithelial cells; (3) SCFA-induced secretion
of IgA by B cells; (4) SCFA-induced promotion of
tissue repair andwound healing; (5) SCFA-induced
promotion of Treg cell development in the gut in a
process that presumably facilitates immunological
tolerance; (6) SCFA (particularly acetate)-mediated
enhancement of epithelial integrity in a process
dependent on inflammasome activation and IL-18
production; and (7) anti-inflammatory effects,
particularly inhibition of NF-kb.
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that Clostridia use to induce Treg cells are unclear. Indeed,
recent reports have shown that SCFAs, particularly butyrate,
directly influence numbers and function of inducible Treg cells
(Arpaia et al., 2013; Furusawa et al., 2013; Smith et al., 2013).
Furthermore, Smith et al. showed that when SCFAs (particularly
acetate and propionate) were fed to germ-free mice, they regu-
lated the size and function of the colonic Treg cell pool (Smith
et al., 2013).
Point 6 in Figure 2 depicts the effects of SCFAs on epithelial
integrity. The best-characterized molecular pathway for mainte-
nance of epithelial integrity involves the inflammasome pathway
and production of the inflammasome-related cytokine inter-
leukin-18 (IL-18) (Dupaul-Chicoine et al., 2010; Elinav et al.,
2011; Normand et al., 2011; Zaki et al., 2010). Recently, mem-
brane hyperpolarization, especially mediated by K+ efflux, or
Ca2+ flux, was found to trigger NALP3 inflammasome activation
(Mun˜oz-Planillo et al., 2013). GPCR signaling is a common
pathway for K+ efflux, or Ca2+ flux, and it is possible that this is
central to the activation of the NALP3 inflammasome and pro-
duction of IL-18. This might be a key mechanism underlying
diet-inducedepithelial integrity and requires further investigation.
Point 7 in Figure 2 depicts the anti-inflammatory effects of
SCFAs, for instance, on inflammatory cytokine production or
on leukocyte recruitment. The ability of SCFAs to inhibit NF-kB
is well known. More specifically, SCFAs have been reported to
reduce expression of vascular cell adhesion protein and intracel-
lular adhesion molecule, production of inflammatory chemo-
kines, and production of inflammatory cytokines tumor necrosis
factor (TNF), IL-6, and interferon-g (Vinolo et al., 2011). The anti-
inflammatory effects of SCFAs on chemotaxis and leukocyte
recruitment have been documented in a number of in vitro
studies, as well as in animal models of inflammation (Maslowski
et al., 2009; Tan et al., 2014).
The actions of SCFAs on the gut, as shown in Figure 2, align
with the results from decades of research showing the health836 Immunity 40, June 19, 2014 ª2014 Elsevier Inc.beneficial effects of either SCFAs or die-
tary fiber, particularly in gut health (Harig
et al., 1989; Kanauchi et al., 2001; Kanau-chi et al., 2002; Scheppach, 1996; Topping and Clifton, 2001;
Treem et al., 1994). In addition to SCFAs, other metabolites—
such as u-3 fatty acids, which inhibit TNF or IL-6 production
from macrophages—show anti-inflammatory properties (Oh
et al., 2010; Yan et al., 2013). The anti-inflammatory properties
of many metabolites presumably relate to the need for con-
strained and well-regulated immune responses to bacterial or
food antigens in the gut. The following sections outline the
main molecular mechanisms whereby metabolites influence
biological outcomes; these mechanisms include ‘‘metabolite-
sensing’’ GPCRs and the effects on gene transcription through
histone deacetylase (HDAC) inhibition or agonism of specific
transcription factors.
Metabolite-Sensing GPCRs
Vertebrates have evolved several mechanisms to respond to
dietary and bacterial metabolites. One mechanism is via metab-
olite-sensing GPCRs, which produce immediate biological re-
sponses to specific metabolites. Many of the common dietary
and bacterial metabolites have GPCR sensors (Figure 3 and
Table 1). The reason that body cells, including immune cells,
use these receptors to modify their function is still uncertain
but presumably relates to a need to sense the availability of
nutrients.
Many of the metabolite-sensing GPCRs listed in Table 1 were
identified as late as the 1990s through large-scale sequencing
efforts, and these sensors were deorphaned in the 2000s
(reviewed in Macia et al., 2012; Tan et al., 2014). Probably the
best-characterized metabolite-sensing GPCRs are GPR43,
GPR41, and GPR109A, which bind SCFAs. GPR43 and
GPR109A appear to be important for gut homeostasis, and
both are expressed by the colonic epithelium, by inflammatory
leukocytes (such as neutrophils and macrophages), and by
Treg cells. Regulation of colonic and peripheral Treg cell
numbers relates to these metabolite-sensing receptors (Singh
et al., 2014; Smith et al., 2013). Lack of GPR109A, a metabolite
Figure 3. Tryptophan Catabolites, Agonism
of AhR, or Stimulation of Metabolite-
Sensing GPCRs
Tryptophan, an essential amino acid, is found in
foodstuffs such as red meat, fish, eggs, and many
vegetables. Tryptophan can be catabolized by
microbial species, such as lactobacilli, to yield
indole-3-aldehyde, an aryl hydrocarbon receptor
(AhR) agonist. Tryptophan can also be transported
across the epithelium by transport machinery
comprising Ace2. Tryptophan is degraded to
kynurenin (an AhR agonist) by the immune-regu-
latory enzyme indoleamine 2,3-dioxygenase
(IDO). After agonist binding, AhR-dependent
gene expression includes genes involved in the
production of mediators important for gut ho-
meostasis; such mediators include IL-22, anti-
microbicidal factors, increased Th17 cell activity,
and the maintenance of intraepithelial lympho-
cytes (IELs) and RORgt+ innate lymphoid cells
(ILCs). A number of tryptophan metabolites,
including kynurenic acid and niacin, agonize
metabolite-sensing GPCRs, such as GPR35 and
GPR109A.
Immunity
Perspectivesensor for butyrate, is associatedwith fewer colonic Treg cells as
a result of the reduced ability of colonic macrophages and DCs
to promote their development (Singh et al., 2014). Deletion of
either receptor in mice exacerbates dextran sulphate sodium
(DSS)-induced colitis (Maslowski et al., 2009; Singh et al.,
2014). Hence, many of the actions described above for SCFAs
in gut homeostasis can be ascribed to GPR43 and GPR109A.
Even though these recent papers show some discrepancies
relating to the relative roles of acetate, propionate, and butyrate,
SCFAs (the main metabolic products of gut bacteria) are used as
a mechanism for tolerance induction in the gut.
Other important metabolite-sensing GPCRs include GPR120,
which recognizes long-chain fatty acids, such as u-3 fatty
acids (Oh et al., 2010), derived from foodstuffs (including fish
and olive oil); GPR91, a receptor for succinate (a product of
the citric acid cycle); GPR84, a receptor for medium-chain fatty
acids, derived from milk in certain species; and GPR35, a re-
ceptor for metabolites of tryptophan catabolism, e.g., kynurenic
acid (Table 1). Some of the most relevant publications associ-
ated with these receptors are referenced in Table 1. All of the
metabolite-sensing GPCRs are expressed by immune cells,
particularly by innate-type cells, although this knowledge has
mostly been gleaned from transcript expression analyses.
They are also expressed on the intestinal epithelium, which
probably relates to roles in maintenance of epithelial integrity.
Another common and defining feature of metabolite-sensing
GPCRs is their expression on tissues or cells relevant to
metabolism, for instance, pancreatic islets or white adipose
tissue. The role of many of these receptors is poorly defined,
and tools for studying their expression and function await
development.
Metabolite-sensing GPCRs have a large bearing on the control
of inflammatory responses, particularly IBD (Maslowski et al.,
2009; Oh et al., 2010; Singh et al., 2014; Trompette et al.,
2014). Indeed, most metabolite-sensing GPCRs and theirligands (including GPR43 and SCFAs, GPR120 and u-3 fatty
acids, GPR109A and its ligands, and possibly GPR35 and its
ligands) facilitate anti-inflammatory effects. Concerning the
SCFA receptors, GPR43-deficient (Ffar2/) mice show exac-
erbated inflammation in models of airway hypersensitivity,
DSS-induced colitis, and rheumatoid arthritis (Maslowski et al.,
2009). Administration of acetate to mice in drinking water pro-
tects against colitis in wild-type mice, but not in Ffar2/ mice,
suggesting that acetate mediates its anti-inflammatory effects
through GPR43. The anti-inflammatory effects of SCFAs are
not limited to GPR43, given that a recent study (Trompette
et al., 2014) established a role for propionate and its receptor
(GPR41) in the generation of macrophage and DC precursors
and in the seeding of the lungs by DCs that have high phagocytic
capacity but an impaired ability to promote Th2 cell responses.
This and other studies from our laboratory clearly establish a
role for fiber intake as protective against allergic airway disease
in mice. Furthermore, it is likely that SCFA-mediated inhibition
of HDAC activity (see below), in addition to SCFA actions on
metabolite-sensing receptors, contributes to the beneficial role
of fiber in diseases such as asthma.
GPR109A has recently emerged as amajor regulator of gut ho-
meostasis. GPR109A binds the SCFA butyrate but also the tryp-
tophan metabolite nicotinic acid. Nicotinic acid is known to have
anti-inflammatory properties, such as inhibition of inflammatory
cytokine secretion by monocytes, macrophages, adipocytes,
and epithelial cells (Digby et al., 2010; Digby et al., 2012; Gamb-
hir et al., 2012; Zandi-Nejad et al., 2013). Nicotinic acid has been
used since the 1950s to reduce progression of atherosclerosis.
More recently, in a mouse model of atherosclerosis, nicotinic
acid was shown to inhibit disease progression in wild-type
mice, but not in mice lacking GPR109A (Lukasova et al., 2011).
This effect was not related to any metabolic changes but instead
depended on GPR109A expression by bone-marrow-derived
cells, such as macrophages.Immunity 40, June 19, 2014 ª2014 Elsevier Inc. 837
Table 1. Summary of Currently RecognizedMetabolite-SensingGPCRs and Their Ligands, SignalingMolecules, EffectorMechanisms,
Expression, and Function
GPCR Ligands Signaling Effector Main Expression Function in Immunity Function in Metabolism
GPR41
(FFAR3)
SCFAs (C3–C7):
formate, acetate,
propionate, butyrate,
pentanoate
Gi/o,
b-arrestin-2
Y cAMP adipocytes,
enteroendocrine
L cells
DC maturation,
anti-inflammatory
(asthma model)
leptin production,
regulation of energy
balance
GPR43
(FFAR2)
SCFAs (C2–C7):
formate, acetate,
propionate, butyrate,
pentanoate
Gi/o, Gq,
b-arrestin-2
Y cAMP, [ Ca2+ innate immune cells,
enteroendocrine
L cells, gut epithelium
white adipose tissue
anti-inflammatory,
gut homeostasis,
tumor suppressor
insulin-mediated fat
accumulation, control
of body energy
GPR109A
(NIACR1,
HM74)
SCFAs (C4-C8):
particularly butyrate
and nicotinic acid
(niacin)
Gi/o,
b-arrestin-2
Y cAMP, [ Ca2+ adipocytes, neutrophils,
macrophages, intestinal
epithelial cells
DC trafficking, gut
homeostasis,
anti-inflammatory,
tumor suppressor
intracellular triglyceride
lipolysis in adipocytes
GPR120
(FFAR4)
long-chain fatty
acids (C14–1C8),
u-3 fatty acids, i.e.,
docosahexaeonic acid
Gq/11,
b-arrestin-2
[ Ca2+ enteroendocrine
cells in the colon,
macrophages
anti-inflammatory,
inhibition of TNF
and IL-6
regulation of insulin
secretion by GLP-1
(role in diabetes?),
FFAR4 SNPs associate
with obesity
GPR40 medium- to long-chain
fatty acids (C12–C18)
Gq/11 [ Ca
2+ pancreatic b cells,
enteroendocrine
K cells
anti-inflammatory insulin secretion from
pancreatic b cells
GPR84 medium-chain fatty
acids (C9–C14), i.e.,
capric acid
Gi/o Y cAMP immune cells proinflammatory?
(role unclear)
role in adiposity?
GPR35 kynurenic acid,
kysophosphatidic
acid, pamoic acid
Gi/o, G16,
b-arrestin-2
Y cAMP, [ Ca2+ monocytes, neutrophils,
iNKT cells, GI tract,
peripheral nervous
tissues, mast cells
GPR35 SNPs
implicated in human
IBD
unstudied
GPR91
(SUCNR1)
Succinate Gi/o, Gq Y cAMP, [ Ca
2+ high levels in adipose
tissue, kidney, nervous
system, DCs; lower levels
in liver, spleen
proinflammatory,
migration of Langerhans
cells, hematopoiesis,
angiogenesis
hypertensive effects,
activation of renin-
angiotensin system
The precise expression and function of many of these metabolite-sensing receptors are still evolving. The information in this table was based in part on
the following studies (only major publications are cited): GPR41 (Samuel et al., 2008; Trompette et al., 2014; Xiong et al., 2004), GPR43 (Kimura et al.,
2013; Maslowski et al., 2009), GPR109A (Lukasova et al., 2011; Singh et al., 2014; Thangaraju et al., 2009), GPR40 (Fujita et al., 2011; Itoh et al., 2003),
GPR120 (Hirasawa et al., 2005; Ichimura et al., 2012; Oh et al., 2010), GPR84 (Suzuki et al., 2013), and GPR35 and GPR91 (Sapieha et al., 2008; Toma
et al., 2008). Metabolite-sensing GPCRs, such as GPR41, GPR120, GPR109A, andGPR43, also play fundamental roles in the regulation of metabolism
and are usually expressed on tissues such as pancreatic islets, adipose tissue, or enteroendocrine cells in the gut. Abbreviations are as follows: cAMP,
cyclic AMP; DC, dendritic cell; GI, gastrointestinal; GLP-1, glucagon-like peptide 1; GPCR, G-protein-coupled receptor; IBD, inflammatory bowel dis-
ease; IL-6, interleukin-6; iNKT, invariant natural killer T cell; SCFA, short-chain fatty acid; and TNF, tumor necrosis factor.
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tabolites produces the aforementioned anti-inflammatory ef-
fects. Several possible outcomes follow the engagement of a
metabolite sensor with its agonist; one example is signaling
through regular G-proteins, such as Gai or Gq, which usually
leads to activation of MAP kinases, PI3 kinases, or mTOR. Inter-
estingly, manymetabolite-sensing GPCRs engage an alternative
signaling pathway mediated by b-arrestin-2 (Oh et al., 2010),
which generally produces anti-inflammatory effects, some of
which relate to inhibition of NF-kB. All of the major metabolite-
sensing GPCRs signal through b-arrestin-2, but the precise cir-
cumstances or cell types that preferentially use b-arrestin-2
have not been determined. b-arrestin-2 directly interacts with
IkBa (an inhibitor of NF-kB), thereby preventing the phosphory-
lation and degradation of IkBa (Gao et al., 2004). It is therefore
predicted that agonism of thesemetabolite-sensing GPCRs trig-
gers an immediate and direct biological response.838 Immunity 40, June 19, 2014 ª2014 Elsevier Inc.Transcriptional and Epigenetic Effects of Dietary and
Bacterial Metabolites
In addition to signaling via GPCRs, some metabolites are also
implicated in regulating transcription through epigenetic path-
ways. Acetylation and deacetylation of histones, as well as
nonhistone proteins (such as transcription factors), are major
mechanisms for epigenetic regulation of gene expression.
Acetylation of histones, by histone acetyl transferases (HATs)
or inhibition of HDACs, results in negatively charged histones,
which, when interacting with negatively charged DNA, loosen
the chromatin structure and result in a transcriptionally active
conformation. Acetylation also promotes the activation, nuclear
translocation, and DNA binding of transcription factors, such as
STAT3, NF-kB, FoxP3, N-FAT, and RUNX1. This leads to the
expression of multiple genes, including those for proinflamma-
tory cytokine production (Wang et al., 2009). Acetylation of tran-
scription factors can also lead to structural changes that alter
Immunity
Perspectivetranscription factor binding to the promoter region, thereby initi-
ating or preventing gene expression. In the case of NF-kB, acet-
ylation of the RelA subunit prevents interaction with IkBa and
results in poor formation and reduced transcriptional interaction
(Chen et al., 2001). Notably, a total of1,750 acetylated proteins
have the potential to be affected by HDAC activity (Choudhary
et al., 2009).
Synthetic small-molecule inhibitors of HDACs have shown the
capacity to attenuate inflammation in animal models of arthritis,
IBD, asthma, diabetes, cardiovascular disease, and multiple
sclerosis (Wang et al., 2009). In addition, the broad HDAC inhib-
itor trichostatin-A increases Treg cell numbers and suppressive
capacity (Tao et al., 2007), illustrating the role of HDAC inhibition
in promoting immunological tolerance in addition to anti-inflam-
matory responses. SCFAs are natural inhibitors of HDAC
enzymatic activity. Of the SCFAs, butyrate is the most potent
HDAC inhibitor, and acetate is the least potent. Butyrate-
induced HDAC inhibition has been shown to regulate macro-
phage function in the intestine and to promote Treg cells (Arpaia
et al., 2013; Chang et al., 2014). Deletion of HDAC3 from intesti-
nal epithelial cells severely disrupts gut homeostasis in the DSS
model (Alenghat et al., 2013), indicating that HDAC3 might play
an important regulatory role in gut homeostasis. Of note, in addi-
tion to inhibiting the enzyme activity, SCFAs might also affect
HDAC gene transcription directly, thereby indirectly influencing
HDAC activity. Therefore, the implications of SCFAs in regulating
transcription through epigenetic pathways must be considered
in future research.
Other Important Metabolites: Tryptophan and u-3 Fatty
Acids
We must consider the independent contribution of gut-micro-
biota-derived metabolites versus metabolites derived directly
from food, such as tryptophan metabolites and u-3 fatty acids.
Tryptophan, an essential amino acid, is found in foodstuffs
such as redmeat, fish, eggs, yogurt, andmany vegetables. Tryp-
tophancanbecatabolizedbymicrobial species, suchas lactoba-
cilli (Figure 3). Indole-3-aldehyde, one tryptophan metabolite
produced by lactobacilli, is an aryl hydrocarbon receptor (AhR)
agonist (Zelante et al., 2013). After agonist binding, AhR trans-
locates to the nucleus, where it forms a heterodimer with AhR
nuclear translocator (ARNT). AhR-dependent gene expression
includes genes involved in the production ofmediators important
for gut homeostasis; these mediators include IL-22, antimicrobi-
cidal factors, increased Th17 cell activity, and themaintenance of
intraepithelial lymphocytes and RORgt+ innate lymphoid cells
(Li et al., 2011; Veldhoen and Brucklacher-Waldert, 2012). The
absence of AhR in mice has been shown to increase the severity
of DSS colitis (Li et al., 2011) andCitrobacter rodentium infection
(Kiss et al., 2011). However, various other metabolites, including
flavonoids andglucosinolates,which are abundant in plants, bind
AhR. Tryptophanmight also be transported across the epithelium
by transport machinery comprising angiotensin I converting
enzyme 2 (ACE2). Deficiency of ACE2 in mice also exacerbates
DSS colitis (Hashimoto et al., 2012), indicating that tryptophan
catabolism in vertebrate tissues is also necessary for proper
gut homeostasis. Tryptophan is converted to kynurenin (also an
AhR agonist) by the immune-regulatory enzyme indoleamine
2,3-dioxygenase (IDO), and IDO activity is linked to suppressionof T cell responses, promotion of Treg cells, and immune
tolerance (King and Thomas, 2007). Moreover, a number of
tryptophan metabolites, including kynurenic acid and niacin, ag-
onizemetabolite-sensingGPCRs, such asGPR35 andGPR109A
(Figure 3). Of note,Gpr35polymorphisms are a genetic risk factor
for IBD (Jostins et al., 2012), and thusmultiple elements of trypto-
phan catabolism facilitate gut homeostasis.
u-3 fatty acidsmight be amajor contributing component of the
beneficial effects of aMediterranean diet. Indeed,u-3 fatty acids
show anti-inflammatory effects through their interaction with the
metabolite sensor GPR120 (Oh et al., 2010). u-3 fatty acids also
show anti-inflammatory effects in animal models and in clinical
intervention studies (Simopoulos, 2002). u-3 fatty acids have
long been suspected as a protective metabolite for asthma,
in part because of observations on Greenland Eskimos, who
consume very high levels of u-3 fatty acids and have extremely
low rates of heart disease and chronic inflammatory diseases,
including asthma (Dyerberg and Bang, 1979). For this popula-
tion, fiber and associated microbiota-derived metabolites might
be less important. The mere existence of metabolite-sensing
GPCRs for tryptophan metabolites and other dietary factors
such as u-3 fatty acids (Oh et al., 2010; Toma et al., 2008) sug-
gests that nonbacterial metabolites are important for regulating
immunity. In all likelihood, the combined effects of both micro-
biota-derived and dietary metabolites operate together.
Concluding Remarks
New understanding of gut microbial ecology, metabolite biology,
metabolite-sensing GPCRs, and transcriptional regulation by
metabolites opens up attractive possibilities for prevention and
treatment of ‘‘Western-lifestyle’’ inflammatory diseases.
Why the mammalian immune system has adopted molecules
traditionally associated with metabolism is intriguing. It is also
unclear why there appears to be a high degree of redundancy
in molecules that regulate gut and immune homeostasis and
why gut homeostasis can be affected by the deletion of any
one of numerous molecules. Determining the relative roles of re-
ceptors such asGPR43, GPR41, andGPR109A versus HDACs is
a necessary task. A confusing aspect of this field is signaling by
metabolite-sensing GPCRs—do receptors signal via b-arrestin-
2, which typically produces anti-inflammatory effects, or through
conventional G-proteins? Irrespective of these unanswered
questions, there exists an opportunity to manipulate immunity
and gut health through metabolite-sensing GPCRs, HDACs,
or transcription factors, such as AhR. One simple approach is
through consumption of healthy foodstuffs, perhaps in combina-
tion with the manipulation of the gut microbiome via probiotics.
This should affect the incidence of many inflammatory diseases
in human populations.
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